Tcr2 Therapeutics Stock Retained Earnings
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Tcr2 Therapeutics fundamentals help investors to digest information that contributes to Tcr2 Therapeutics' financial success or failures. It also enables traders to predict the movement of Tcr2 Stock. The fundamental analysis module provides a way to measure Tcr2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tcr2 Therapeutics stock.
Tcr2 |
Tcr2 Therapeutics Company Retained Earnings Analysis
Tcr2 Therapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Tcr2 Therapeutics Retained Earnings | (501.34 M) |
Most of Tcr2 Therapeutics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tcr2 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Tcr2 Therapeutics has a Retained Earnings of (501.34 Million). This is 153.83% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 105.37% higher than that of the company.
Tcr2 Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tcr2 Therapeutics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tcr2 Therapeutics could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics of similar companies.Tcr2 Therapeutics is currently under evaluation in retained earnings category among its peers.
Tcr2 Fundamentals
| Return On Equity | -0.91 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | (73.69 M) | |||
| Shares Outstanding | 39.26 M | |||
| Shares Owned By Insiders | 1.50 % | |||
| Shares Owned By Institutions | 54.31 % | |||
| Number Of Shares Shorted | 360.89 K | |||
| Price To Book | 0.22 X | |||
| EBITDA | (89.62 M) | |||
| Net Income | (151.82 M) | |||
| Cash And Equivalents | 175.99 M | |||
| Cash Per Share | 4.55 X | |||
| Total Debt | 58.23 M | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 5.02 X | |||
| Book Value Per Share | 2.58 X | |||
| Cash Flow From Operations | (101.46 M) | |||
| Short Ratio | 1.29 X | |||
| Earnings Per Share | (4.20) X | |||
| Target Price | 6.43 | |||
| Number Of Employees | 58 | |||
| Beta | 1.93 | |||
| Market Capitalization | 58.11 M | |||
| Total Asset | 208.24 M | |||
| Retained Earnings | (501.34 M) | |||
| Working Capital | 113.56 M | |||
| Z Score | -3.54 | |||
| Net Asset | 208.24 M |
About Tcr2 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tcr2 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tcr2 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tcr2 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tcr2 Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Tcr2 Stock
| 0.86 | JNJ | Johnson Johnson | PairCorr |
| 0.79 | PTAIF | PT Astra International | PairCorr |
| 0.79 | PTITF | PT Indosat Tbk Earnings Call This Week | PairCorr |
| 0.78 | XOM | Exxon Mobil Corp Earnings Call Today | PairCorr |
| 0.75 | TRV | The Travelers Companies | PairCorr |
The ability to find closely correlated positions to Tcr2 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tcr2 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tcr2 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tcr2 Therapeutics to buy it.
The correlation of Tcr2 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tcr2 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tcr2 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tcr2 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |